The third trial of the co-vaccine, which began in mid-October, has been postponed for about 15 days at the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, Uttar Pradesh’s capital.
Earlier, the trial of the corona virus vaccine was scheduled to begin from October 15 at SGPGI and some other places in the country including BRD Medical College, Gorakhpur. The Director of SGPGI, Professor Radha Krishna Dhiman, said on Wednesday that the results of the Phase 2 trial of the co-vaccine are still being evaluated by the Drug Controller General of India. Therefore, the next phase of trials is expected to begin in the last week of October.
The Co-vaccine is the first indigenously developed corona virus vaccine. It was trialled in phase 1 and 2 at 12 centers across the country by Biotech and National Institute of Virology of India. He explained that the Phase 3 trial of the Co-vaccine is very important. This would be the final decision before giving the green signal for the production of the vaccine. So far, the first two stages of the co-vaccine have yielded promising results.
Meanwhile, the number of active patients in Uttar Pradesh was decreasing for the last 24 days and after recording the peak on 17 September it was reduced by about 44 percent.
Significantly, the third trial of PGI Co-vaccine based in Lucknow was scheduled to start in mid-October. The PGI administration has prepared its action plan. On September 24, Chief Minister Yogi Adityanath approved the trial of PGI of Corona vaccine ‘Co-vaccine’ being developed by Bharat Biotech and BRD Medical College of Gorakhpur. The trial will be conducted in two different age groups. Those who have not been exposed to corona infection. However, these will include diabetes, blood pressure, thyroid etc. in serious patients.